Xconomy | Seattle - Business + Technology in the Exponential Economy

Seattle Genetics Starts New Trial

Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, said today it has started a mid-stage clinical trial of SGN-35 as a treatment for relapsed forms of anaplastic large cell lymphoma. The trial will enroll 55 patients, who will the same dose every three weeks as the one being used in an ongoing pivotal trial of Hodgkin’s disease and related lymphomas. The Seattle Genetics (NASDAQ: SGEN) drug is designed to be an “empowered antibody” that adds a potent toxin to an antibody to give it more tumor-killing punch.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: